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The effect of transforming growth factor b1 gene
polymorphisms in ankylosing spondylitis
E. Jaakkola, A. M. Crane, K. Laiho2, I. Herzberg, A.-M. Sims,
L. Bradbury, A. Calin1, S. Brophy1, M. Kauppi2, K. Kaarela2,
B. P. Wordsworth, J. Tuomilehto3,4 and M. A. Brown
Objectives. To determine whether genetic polymorphisms in or near the transforming growth factor 1 (TGFB1) locus were
associated with susceptibility to or severity of ankylosing spondylitis (AS).
Methods. Five intragenic single-nucleotide polymorphisms (SNP) and three microsatellite markers ﬂanking the TGFB1 locus
were genotyped. Seven hundred and sixty-two individuals from 184 multiplex families were genotyped for the microsatellite
markers and two of the promoter SNPs. One thousand and two individuals from 212 English and 170 Finnish families with AS
were genotyped for all ﬁve intragenic SNPs. A structured questionnaire was used to assess the age of symptom onset, disease
duration and disease severity scores, including the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI
(Bath Ankylosing Spondylitis Functional Index).
Results. A weak association was noted between the rare TGFB1 þ1632 T allele and AS in the Finnish population (P¼ 0.04)
and in the combined data set (P¼ 0.03). No association was noted between any other SNPs or SNP haplotype and AS, even
among those families with positive non-parametric linkage scores. The TGFB1 þ1632 polymorphism was also associated with a
younger age of symptom onset (English population, allele 2 associated with age of onset greater by 4.2 yr, P¼ 0.05; combined
data set, allele 2 associated with age of onset greater by 3.2 yr, P¼ 0.02). A haplotype of coding region SNPs (TGFB1 þ869/
þ915þ1632 alleles 2/1/2) was associated with age of symptom onset in both the English parent–case trios and the combined
data set (English data set, haplotype 2/1/2 associated with age of onset greater by 4.9 yr, P¼ 0.03; combined data set,
haplotype 2/1/2 associated with greater age of onset by 4.2 yr, P¼ 0.006). Weak linkage with AS susceptibility was noted and
the peak LOD score was 1.3 at distance 2 cM centromeric to the TGFB1 gene. No other linkage or association was found
between quantitative traits and the markers.
Conclusion. This study suggests that the polymorphisms within the TGFB1 gene play at most a small role in AS and that other
genes encoded on chromosome 19 are involved in susceptibility to the disease.
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Ankylosing spondylitis (AS) exhibits a strong genetic component
determining both the susceptibility to and the severity of the
disease; except for HLA B27, the genes responsible have not
been deﬁnitely identiﬁed [1, 2]. Non-major histocompatibility
complex (MHC) genes are estimated to account for at least half
of the genetic variance of AS susceptibility [3]. The male:female
ratio for AS is between 2.5:1 and 5:1 [4], but the gender bias is
not explained by the linkage to the X chromosome [5]. The gene
(TGFB1) for transforming growth factor (TGF)1 is located on
chromosome 19q13, where suggested evidence of linkage was
reported in both our whole-genome screen [6] and the North
American Spondylitis Consortium genome screen [7]. The peak
of linkage on chromosome 19 in our genome screen was
observed with the marker D19S420 [LOD (log of the odds) score
3.58], which is located 1.8 Mb from the TGFB1 gene. Strong
evidence of linkage to chromosome 19 was also identiﬁed in a
genome-wide scan for loci for susceptibility to inﬂammatory
bowel disease (IBD) [8], a disease that is clinically associated
with spondyloarthritis.
TGF-1 plays a crucial role in inﬂammatory processes,
extracellular matrix synthesis, bone remodelling and ﬁbrosis and
may be important in the biological pathways related to the
expression of AS [9]. TGF-1 is proﬁbrotic and is possibly also
responsible for late-stage ﬁbrosis and ankylosis. TGF-1 acts in
the formation and repair of cartilage and bone [10], which are the
major targets of the immune response in AS. TGF-1 promotes
immunoglobulin A (IgA) class-switching in B cells. Increased levels
of serum IgA against Gram-negative bacteria have been reported
among AS patients [11–13]. AS is associated with an impaired Th1
cytokine proﬁle [14], and TGF-1 can inhibit the production of
and response to cytokines associated with both Th1 and Th2
cells [15]. TGF-1 suppresses the expression of class II MHC
antigens induced by interferon- [16]. TGF-1 has multiple
suppressive actions on T cells, B cells and macrophages, and
increased TGF-1 production has been shown to inhibit
autoimmune and chronic inﬂammatory diseases [17]. In animal
models, systemic delivery of TGF-1 or intramuscular injection of
TGF-1 plasmid inhibits acute and chronic arthritis [18]. We have
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investigated the effect of the positional and functional candidate
gene TGFB1 on susceptibility to and severity of AS in an English
and a Finnish population.
Patients and methods
Families with AS
One thousand three hundred and thirty-three individuals from 212
parent–case trio families and 184 AS affected-sibling pair families
were recruited from the UK. AS patients were identiﬁed from
several sources: the Royal National Hospital for Rheumatic
Diseases AS database; patients attending the Nufﬁeld Orthopaedic
Centre, Oxford; in response to public appeals; and by referral from
British rheumatologists. Among the parent–case trios there were
31 parent–case affected pairs; other families were simplex, i.e. there
was one affected subject in the family. There were 437 individuals
in the 170 Finnish families recruited from the Rheumatism
Foundation Hospital in Heinola, Finland. These included 12
affected sibling pairs, 11 parent–case affected pairs and 147
simplex families. Both the English and Finnish patients and
families had been included in previous studies [6, 19, 20]. Patients
who showed clinical evidence of primary AS and fulﬁlled the
modiﬁed New York diagnostic criteria [21] were selected for the
study. Sacroiliitis was conﬁrmed by a qualiﬁed radiologist and
the diagnosis of AS was conﬁrmed by a qualiﬁed rheumatologist.
All the patients were >16 yr old. Genomic DNA was prepared
from peripheral venous blood by standard methods. A structured
questionnaire was used to assess the presence of acute anterior
uveitis (AAU), IBD, psoriasis and peripheral arthritis, age of
symptom onset, age at diagnosis, disease duration and disease
severity scores, including the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) [22] and the Bath Ankylosing
Spondylitis Functional Index (BASFI) [23]. The study protocol
reported here was approved by research ethics committee boards in
both England and Finland. All participants gave informed consent
prior to enrolment.
HLA B27, TGFB1 SNP and microsatellite genotyping
We genotyped ﬁve polymorphisms located in the promoter and
coding region of the TGFB1 gene and three microsatellite markers
ﬂanking the TGFB1 locus in families with AS. One thousand and
seven individuals from 212 English and 170 Finnish families with
AS were genotyped for all the ﬁve SNPs. Seven hundred and sixty-
two individuals from 184 multiplex families with AS were typed for
the two polymorphisms in the promoter region of the TGFB1 gene
and three microsatellite markers. SNP genotyping was performed
using the polymerase chain reaction–sequence speciﬁc primer
(PCR-SSP) method [24] (800 G/A, 509 C/T, þ869 T/C, þ915
G/C andþ1632 C/T). Positive and negative controls were included
in all the reactions. The same positive controls were used in both
the Finnish and the English data set and all ambiguous samples
were repeated. HLA B27 was detected by the method described by
Bunce et al. [25]. Families with an HLA B27-positive proband were
included in the analysis.
Three microsatellites spanning 6.4 centimorgans (cM) around
the TGFB1 locus were genotyped: d19s421, d19s223 and d19s217.
The microsatellites were ampliﬁed under optimized PCR condi-
tions, and the PCR products were separated and detected by
capillary electrophoresis using an ABI Prism 3700 genotyper
(Applied Biosystem, Warrington, UK). Products were then sized
and manual inheritance checks performed using Genotyper version
1.1 (PE Biosystem, Foster City, CA, USA) and Genescan version
2.1 (PE Biosystems).
Statistical analysis
Mendelian inheritance of markers was checked using the program
GAS (version 2.0) [unpublished, A. Young]. The 2 test for a 3 2
contingency table was used to examine whether the genotype
frequencies were in Hardy–Weinberg equilibrium. P>0.05 was
accepted as indicating non-signiﬁcant deviation from Hardy–
Weinberg equilibrium. Association between TGFB1 polymor-
phisms and disease susceptibility was studied with the transmission
disequilibrium test (TDT) using the program Transmit (version
2.5) [26]. P values were obtained by statistical simulation using
1000 replicates, using the robust variance option to assess
association independent of linkage. Non-parametric linkage
analysis was performed using the program Genehunter-Plus for
qualitative data [27] and Merlin-Regress for quantitative data [28].
Association was evaluated in a subset of families which showed a
positive non-parametric linkage score. Association between
TGFB1 polymorphisms and the age of symptom onset, BASDAI
and BASFI was assessed using the Quantitative Transmission
Disequilibrium Test (QTDT) [29]. Population stratiﬁcation and
total evidence of association were assessed using QTDT. TGFB1
haplotypes were constructed using the Phase program [30].
Mendelian inheritance of haplotypes was checked manually and
only haplotypes which were constructed with >90% certainty
were accepted for further analysis. These haplotypes were used as
input for QTDT to assess the association between TGFB1
haplotypes and the age of symptom onset, BASDAI and BASFI.
BASFI and BASDAI were correlated with disease duration and
gender in this data set and were treated as covariates in the
analysis. The association between the polymorphisms and the
presence of AAU, peripheral arthritis or IBD was studied using the
2 test. For the inter-ethnic comparison, the haplotypes were
constructed using the program Transmit [26]. The pairwise linkage
disequilibrium (LD) between the SNPs was calculated using
Lewontin’s standardized disequilibrium coefﬁcient D0 [31],
calculated using the program HaploXT [32]. The program
Entropy was used to identify the subset of SNPs that best
approximates the haplotypic diversity in the population [www.wel-
l.ox.ac.uk/rmott/SNPS]. The power of the study to detect
association with susceptibility to AS was determined using TDT
Power Calculator [33]. This program does not allow for missing
parents in the data, and thus in our study gave an overestimate of
the actual power.
Results
Clinical description of the families
The clinical characteristics of the AS patients are described in
Table 1.
Disease susceptibility
Transmitted and untransmitted marker and SNP haplotype
frequencies estimated using Transmit are given in Tables 2 and 3.
TABLE 1. Clinical description of the AS patients
English AS Finnish AS
BASFI 3.6 2.7 3.7 2.2
BASDAI 3.9 2.1 5.2 1.8
Age at symptom onset (yr) 22.4 7.6 26 8.0
Disease duration (yr) 22.0 13 20 10
Males, females (%) 381 (63), 224 (37) 122 (64), 70 (36)
AAU (%) 222 (37) 79 (52)
IBD (%) 38 (6.3) 10 (6.5)
Peripheral arthritis (%) Not available 119 (76)
Data are mean (S.D.) or n (%).
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By within-family analysis, a marginal association was noted
between the rare TGFB1 þ1632 T allele and AS in a Finnish
population (4.2 vs 5.3%, P¼ 0.04) and in the combined data set
(2.8 vs 3.7%, P¼ 0.03), but not in the English data set alone (1.7 vs
1.9%, P¼ 0.79). No association was noted between any other SNP
or marker haplotype and AS.
Non-parametric linkage analysis and evaluation
of association among the families showing
linkage to the TGFB1 locus
The multipoint non-parametric linkage analysis using Genehunter
Plus showed weak evidence of linkage centromeric to the TGFB1
locus. The highest LOD score was obtained 2 cM centromeric from
the TGFB1 gene between the markers d19s421 and d19s223, the
peak LOD score being 1.3 (P¼ 0.02) at 63 cM from the p-telomere.
Ninety-six families showed a positive non-parametric linkage
(NPL) score, but no association was detected between AS and
TGFB1 800 or 509 polymorphisms among these families.
TGFB1 þ1632 C/T polymorphism, which showed a weak asso-
ciation, was not genotyped in the subgroup of families with a
positive NPL score, because of the LD between this SNP and the
promoter polymorphisms.
Disease severity results
Association was noted between age at symptom onset and TGFB1
polymorphisms in different populations, but this was not
consistently observed in the three family collections. In the
English parent–case trio families, association with age at onset was
TABLE 2. Frequencies of untransmitted and transmitted founder marker alleles of TGFB1, and TDT P values
Untransmitted founder
alleles
Transmitted founder
alleles
Marker Ethnic group Allele SNP nucleotide n % n % P
800 Finnish 1 G 374 94 373 94 0.68
2 A 24 6 25 6
English 1 G 1115 91 1128 92 0.06
2 A 109 9 96 8
509 Finnish 1 C 297 75 294 74 0.51
2 T 101 25 104 26
English 1 C 905 74 901 74 0.65
2 T 319 26 323 26
869 Finnish 1 T 294 74 292 74 0.67
2 C 102 26 104 26
English 1 T 267 65 260 63 0.29
2 C 143 35 150 37
915 Finnish 1 G 378 95 381 96 0.26
2 C 18 5 15 4
English 1 G 375 91 377 92 0.7
2 C 37 9 35 8
1632 Finnish 1 C 378 96 373 95 0.04
2 T 16 4 21 5
English 1 C 406 98 404 98 0.34
2 T 8 19 10 2
TABLE 3. Frequencies of untransmitted and transmitted founder SNP (800, 509,þ869,þ915,þ1632) haplotypes in the Finnish (n¼ 388) and English
(n¼ 414) populations
Untransmitted founder
haplotypes
Transmitted founder
haplotypes
Haplotypea n % n % P
English population (n¼ 414) (n¼ 414)
11111 221 53 227 55 0.39
12211 99 24 104 25 0.41
21111 35 8 28 7 0.70
11221 28 7 32 8 0.35
12212 8 2 9 2 0.44
11211 9 2 6 1 0.23
11121 7 2 4 1 0.21
12111 4 1 2 0.5 0.27
Finnish population (n¼ 388) (n¼ 388)
11111 243 63 246 63 0.62
12211 72 19 74 19 0.63
21111 22 6 24 6 0.65
11221 12 3 9 2 0.29
12212 12 3 15 4 0.26
12111 12 3 9 2 0.24
12112 4 1 2 0.5 0.2
Only haplotypes with frequency >1% are shown.
a1, wild-type allele; 2, rare allele.
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noted forTGFB1509 (allele 2 associated with age of onset greater
by 2.1 yr,P¼ 0.007) andþ1632 (allele 2 associatedwith age of onset
greater by 4.2 yr, P¼ 0.05), haplotypes of the promoter region
variants 800/509 (haplotype 1/1 associated with age of onset
lower by 1.8 yr,P¼ 0.02; haplotype 1/2 associated with age of onset
greater by 2.1 yr, 0.007), and haplotypes of the coding region
variantsþ 869/þ915/þ1632 (haplotype 1/1/1 associated with age of
onset lower by 1.7 yr, P¼ 0.01; haplotype 2/1/1 associated with age
of onset greater by 1.8 yr, P¼ 0.03; haplotype 2/1/2 associated with
age of onset greater by 4.9 yr, P¼ 0.03). The promoter region
associations were not replicated in the English affected sibling pair
families, and when all English families were analysed together no
signiﬁcant association was noted for TGFB1800 or509 or their
haplotypes. When we pooled English and Finnish families geno-
typed for the coding region polymorphisms, weak association was
noted forTGFB1þ915 (allele 1 associated with age of onset greater
by 2.5 yr, P¼ 0.01) andþ1632 (allele 2 associated with age of onset
greater by 3.2 yr, P¼ 0.02) variants, and haplotypes of coding
region polymorphisms þ869/þ915/þ1632 (haplotype 2/2/1 asso-
ciated with age of onset lower by 2.3 yr, P¼ 0.05; haplotype 2/1/2
associated with age of onset greater by 4.2 yr, P¼ 0.006). No
signiﬁcant association was observed with age of symptom onset in
the Finnish families, although the data set was too small to provide
adequate power to exclude a signiﬁcant association, particularly of
haplotypes.
No effect of population stratiﬁcation on these associations was
noted in the data set. No other associations were noted between
quantitative traits and any of the polymorphisms. No linkage was
found between quantitative traits and the SNPs. No signiﬁcant
association between the polymorphism and the presence of AAU,
peripheral arthritis or IBD was noted in this study.
Power of the study
We calculated the power of our study for dominant, codominant
and recessive modes of inheritance, assuming prevalence of 0.1%
for AS and type I error of 0.05. For dominant and codominant
models, the study had 80% power to detect association of loci with
genotype relative risks of 1.4–3.1 depending on the SNP concerned.
For recessive models, the power was poor for the TGFB1þ915 and
þ1632 polymorphisms (80% power for genotype relative risks of
10.2–26), but moderate for the other SNPs (80% power for
genotype relative risks of 1.9–4.6).
Linkage disequilibrium and haplotype studies
We compared the founder allele frequencies between our Finnish
and English data sets and the control individuals in two previously
published British studies [34, 35]. No signiﬁcant differences in allele
frequencies were noted between our English data set and the
previous studies. The allele frequencies of TGFB1 800, þ869 and
þ915 polymorphisms showed signiﬁcant differences between our
Finnish data set and both our English data set and the two
previously published British studies (P¼ 3 103, P¼ 108 and
P¼ 5 105 respectively).
Of the 32 possible SNP haplotypes, two main haplotypes
accounted for 79% of all haplotypes (Table 4), which is consistent
with previous reports [34, 36]. Eight haplotypes with a frequency
of >1% were identiﬁed. Signiﬁcant differences were noted in
haplotype frequencies between the Finnish and English popula-
tions [test of homogeneity, 2 (8 degrees of freedom)¼ 107,
P<1010].
Table 5 shows values of D0 between the SNPs in the two
populations, and the corresponding P values. By inspection, there
are signiﬁcant differences in the LD patterns between the English
and Finnish populations.
Entropy values for different combinations of SNPs are given in
Fig. 1. Two promoter SNPs and the TGFB1 þ869 T/C poly-
morphism account for 85% of the total diversity observed for
all ﬁve SNPs in the Finnish population and 87% in the English
population.
TABLE 4. Localization of SNPs and identiﬁcation of haplotypes of the TGFB1 gene
Nucleotide Frequency Frequency
Alleles 800 509 þ869 þ915 þ1632 n (%) n (%)
Haplotype G/A C/T T/C G/C C/T English Finnish
1 G C T G C 1351 (0.52) 532 (0.62)
2 G T C G C 650 (0.25) 154 (0.18)
3 A C T G C 208 (0.08) 51 (0.06)
4 G C C C C 182 (0.07) 26 (0.03)
5 G C C G C 52 (0.02) 5 (0.006)
6 G T T G C 26 (0.01) 34 (0.04)
7 G T C G T 52 (0.02) 26 (0.03)
8 G C T C C 26 (0.01) 9 (0.01)
9 G T T G T 0 9 (0.01)
Location 50 50 Codon 10 Codon 25 Codon 263
Leu/Pro Arg/Pro Thr/Pro
Haplotypes with frequency greater than 1% are shown. There were 2598 haplotypes in the English cohort and 858 haplotypes in the Finnish cohort.
TABLE 5. LD values between the SNPs for the combined data set
Polymorphism Ethnic group 509 C/T þ869 T/C þ915 G/C þ1632 C/T
800 G/A Finnish 0.88 (0.002) 0.88 (0.002) 0.41 (0.6) 0.39 (0.6)
English 0.79 (0) 0.87 (0) 1 (0.007) 1 (0.2)
509 C/T Finnish 0.64 (0) 0.74 (0.02) 0.76 (0)
English 0.77 (0) 0.63 (0.0008) 0.73 (0)
þ869 T/C Finnish 0.58 (0) 0.46 (0)
English 0.64 (0) 0.69 (0.0002)
þ915 G/C Finnish 0.32 (0.7)
English 1 (0.2)
The table shows Lewontin’s standardized disequilibrium coefﬁcient D0 (P value). All calculations are based on 1 degree of freedom.
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Discussion
TGFB1 is an attractive positional and functional candidate gene
for AS due to its position under the chromosome 19 linkage peak
and involvement of the gene product in inﬂammatory processes,
tissue ﬁbrosis and bone remodelling. Suggested linkage to
chromosome 19 was identiﬁed in our whole-genome screen of
AS, the maximum overall LOD score detected being 3.5 [6]. A
recent North American Spondylitis Consortium genome screen in
AS also detected linkage on chromosome 19, giving further
evidence that genes on chromosome 19 are involved in AS [7].
Genome-wide screening in IBD has identiﬁed strong linkage with
chromosome 19 [8], which may be a relevant ﬁnding in AS
pathology as subclinical ileitis is found in 49% of patients with AS
[37] and these diseases may share common underlying predisposing
genes. Our study noted a weak association between the rare
TGFB1 þ1632 T allele and susceptibility to AS and age of
symptom onset. However, the lack of association of TGFB1
promoter polymorphisms, which are in tight LD with the TGFB1
þ1632 alleles, with AS in families with positive NPL scores at the
locus indicates that these polymorphisms do not explain the
observed linkage of chromosome 19 with disease susceptibility. It
should be noted that the P values reported here are not corrected
for the multiple comparisons involved, as the number
of independent comparisons would be difﬁcult to determine.
However, the positive P values reported are unlikely to be
signiﬁcant if such correction is employed, and these ﬁndings will
require further conﬁrmation.
Polymorphisms of TGFB1 have been implicated in a variety
of musculoskeletal diseases, including rheumatoid arthritis [38],
systemic sclerosis [39] and osteoporosis [40, 41]. An association
between the TGFB1þ869 CC genotype and both ossiﬁcation of the
posterior longitudinal ligament in the cervical spine and spinal
osteophytosis has been reported in Japanese patients [42, 43].
No association between IBD or Crohn’s disease and TGFB1
polymorphisms was found in previous studies [44, 45]. A recent
study from Scotland reported an association between TGFB1þ915
polymorphism and AS, and demonstrated association of this
genotype with higher serum concentrations of TGFB1 [46]. We
noted a weak association between age of symptom onset and this
polymorphism in both the combined and in the Finnish data set.
Taking these ﬁndings together, we conclude that this TGFB1
polymorphism may play a role in AS, though a very weak one.
Our study failed to replicate the association of TGFB1 þ915
polymorphism with AS susceptibility. Marked differences in LD
patterns were noted between the two populations. It is possible that
the differences between our observations in the English and Finnish
populations and the difference between our results and those
previously reported in a Scottish population may reﬂect differential
association with a further, truly associated polymorphism.
In searching for disease genes for complex traits, it has been
suggested that substantial advantage can be obtained by gaining
access to multiple populations with divergent demographic
histories [47]. We studied TGFB1 polymorphisms in a Finnish
and an English population, which were both of white Caucasian
descent and had well-characterized population histories. We noted
marked differences in allele and haplotype frequencies, disease
associations and LD pattern between these two populations. Our
results suggest that these populations have distinct population
histories and that different TGFB1 haplotypes have been traded
differently by drift. Previous studies have demonstrated that
disequilibrium levels are not substantially greater in the general
Finnish population than in the UK population [48, 49]. However,
LD varies drastically across the genome and these studies were
limited to two chromosomal regions in the genome. To our
knowledge, no studies investigating the disequilibrium between a
Finnish and an English population at the TGFB1 locus have been
conducted previously. Additionally, small LD differences, such as
those observed in our study, especially within genes, may be rel-
evant in the location of the causative disease-associated variants.
The TGFB1 gene consists of seven exons encompassing 23.5 kb
on chromosome 19q13.1. Three SNPs in the promoter region, one
insertion/deletion in the 50 untranslated region, two SNPs in the
signal peptide sequence, one SNP in intron 4 and one SNP in exon
5 have been identiﬁed previously [41, 50]. Polymorphism at
positions þ869 T/C and þ915 G/C in the signal protein sequence
of the TGFB1 gene change codon 10 (Leu10-Pro) and codon 25
(Arg25-Pro) respectively, and polymorphism in exon 5 at position
þ1632 C/T changes codon 263 (Thr263-Ile). We typed all the
known polymorphisms in the TGFB1 gene except the 988 C/A,
þ72 insertion and 713–8delC [41]. The TGFB1 þ72 insertion
was not included in the study as it exhibits almost complete LD
with the TGFB1 þ915 polymorphisms [50]. TGFB1 988 C/A and
713–8delC were excluded because their low frequency would make
our current sample size inadequate to achieve required power [33].
Haplotypic analysis is usually more powerful than studying
individual polymorphisms in LD mapping, and haplotype-based
methods have recently contributed to the identiﬁcation of genes for
complex diseases [51–53]. During recent decades, haplotype-based
analyses have commonly been used successfully in HLA genetics
[54, 55]. We aimed to capture all the common variation within the
TGFB1 locus and hence constructed haplotypes within this region.
Two major haplotypes accounted for 79% of the total number of
haplotypes in our data set. This conservation of haplotypes may be
attributable to the fact that all the individuals in our study were
of Caucasian origin, or it may suggest that selective pressure acts
on this functionally important locus. We attempted to assess the
diversity of this locus using the program Entropy. The promoter
polymorphisms and the TGFB1 þ869 T/C variant account for
most of diversity at this locus and a relatively small increase in
diversity is attributable to the rare variants TGFB1 þ915 G/C and
þ1632 C/T. This observation enables targeted SNP selection in
association studies of common complex diseases, where underlying
disease causing variants are likely to be of relatively high
frequency.
In vivo, TGF-1 acts in combination with other peptide growth
regulators, such as epidermal growth factor and its homologue
TGF-, platelet-derived growth factor and basic ﬁbroblast growth
factor. The synthesis, secretion, activation and tissue-speciﬁc
expression of TGF-1 are tightly regulated processes.
Understanding of the true role of TGF-1 in disease pathogenesis
would require dissection of these interactions and the regulation of
TGFB1. Other TGF- isoforms, such as TGF-2 and TGF-3, and
other related molecules, such as TGF- receptors, latent TGF-
binding proteins and other regulatory molecules, may play a role in
FIG. 1. Entropy in the Finnish and English data sets. Values
are given for the following SNPs: 1¼ 869 T/C; 2¼ 869 T/C
and 509 C/T; 3¼ 869 T/C, 509 C/T and 800 G/A; 4¼ 869
T/C, 509 C/T, 800 G/A and 915 G/C; 5¼ 869 T/C, 509
C/T, 800 G/A, 915 G/C and 1632 C/T.
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the pathology of AS. The latent TGF- binding protein 4 gene and
the ﬁbroblast growth factor 22 precursor gene are located on
chromosome 19 (19q13.2 and 19p13.3, respectively) and they are
potentially interesting positional candidate genes in AS. Several
polymorphisms have been found in the TGF- III receptor gene
[56], which could potentially affect TGF- signalling. TGF-2
mRNA has been detected in biopsy specimens from the
sacroiliac joints of patients with AS, suggesting that TGF-2
may play an active role in sacroiliitis [57]. TGF-2 is
abundantly present in the anterior chamber of the eye and
could potentially be involved in the pathogenesis of AAU [58].
It is also likely that yet unknown gene–gene interactions or
gene–environment interactions play a signiﬁcant role in AS
pathology. To study these issues would require a completely
different study design.
It has been demonstrated that the plasma concentration of
active and acid-activatable latent TGF-1 is predominantly
under genetic control (heritability estimate 0.54). The 509 C/T
promoter polymorphism in the TGFB1 gene has been shown to be
signiﬁcantly associated with higher concentrations of TGF-1,
explaining 8.2% of the additive genetic variance in TGF-1
concentration [59]. Furthermore, the polymorphisms at positions
þ869 T/C and þ915 G/C in the signal protein sequence of the
TGFB1 gene, which change codon 10 (Leu10-Pro) and codon 25
(Arg25-Pro) respectively, have been reported to be related to
variations in the production of TGF-1 [35, 40]. However, it
remains to be determined whether differences in the circulating
concentration of TGF-1 among individuals with different TGFB1
genotypes affect the concentrations of the cytokine in the sacroiliac
joints and entheses. The local effects of TGF-1 in AS require
further elucidation. TGF-1 may have a promising therapeutic
potential for AS, and our ﬁndings do not exclude a key role of
TGF-1 protein in the pathogenesis of AS. Our study suggests that
TGFB1 polymorphisms play a minor role in AS and do not explain
the linkage of chromosome 19 to AS susceptibility.
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